Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid (INT-747) monotherapy in primary biliary cirrhosis
2007-001424-12Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Primary endpoint: Serum alkaline phosphatase reduction. Started Sep 2007; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2007-001424-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001424-12.